Ending four years of legal fight, ARCH-backed synthetic DNA maker settles lawsuit with CEO's former employer
When Twist Bioscience filed for an IPO in 2018, one issue featured prominently in the sections where execs warned investors about the risks related to their synthetic DNA business.
We and our chief executive officer are currently involved in litigation with Agilent in which Agilent has alleged a claim of trade secret misappropriation against our Company and trade secret misappropriation and other related claims against our chief executive officer. This litigation with Agilent could result in significant expense. Agilent has considerable resources available to it; we, on the other hand, are an early-stage commercial company with comparatively few resources available to us to engage in costly and protracted litigation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.